Avelumab as second-line or later (2L+) treatment (tx) in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Real-world tx patterns in France

被引：0
|
作者：
Fily, A. Blom [1 ]
Mortier, L. [2 ]
Van Hille, B. [3 ]
Samimi, M. [4 ]
Luciani, L. [3 ]
Cahuzac, C. [3 ]
Robert, C. [5 ]
Quereux, G. [6 ]
Maubec, E. [7 ]
Maillard, C. [8 ]
Miotti, H. [8 ]
Aubin, F. [9 ,10 ]
Lenormand, C. [11 ]
Solbes, M-N. [3 ]
Modeste, A. B. Duval [12 ]
Kachaner, I. [13 ]
Lebbe, C. [14 ]
Dutriaux, C. [15 ]
Saiag, P. [1 ]
机构：
[1] CHU Ambroise Pare, Boulogne, France
[2] CHU Lille, Serv Dermatol, Hop Claude Huriez, Lille, France
[3] Merck Sante SAS, Lyon, France
[4] CHU Tours, Hop Trousseau, Tours, France
[5] Inst Gustave Roussy, Villejuif, France
[6] CHU Nantes, Hop Hotel Dieu, Nantes, France
[7] Hop Avicenne, APHP, Bobigny, France
[8] IQVIA Operat France, La Def, France
[9] CHU, Dermatol, Besancon, France
[10] Inserm 1098, Besancon, France
[11] Hop Univ Strasbourg, Serv Dermatol, Mcu Ph, Strasbourg, France
[12] CHU Rouen, Hop Charles Nicolle, Rouen, France
[13] Pfizer, Paris, France
[14] Univ Paris Cite, Dermatooncol, Hop St Louis, AP HP,CIC, Paris, France
[15] CHU Bordeaux, Hop St Andre, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2282
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1148P
引用
收藏
页码：S687 / S687
页数：1
相关论文
共 50 条
  • [1] Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database.
    Fily, Astrid Blom
    Mortier, Laurent
    Kachaner, Isabelle
    Meyer, Nicolas
    Samimi, Mahtab
    Luciani, Laura
    Cahuzac, Capucine
    Robert, Caroline
    Quereux, Gaelle
    Maubec, Eve
    Maillard, Cathy
    Miotti, Hakima
    Aubin, Francois
    Lenormand, Cedric
    Solbes, Marie-Noelle
    Joly, Pascal
    van Hille, Benoit
    Lebbe, Celeste
    Dutriaux, Caroline
    Saiag, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP)
    Walker, John
    Kasturi, Vijay
    Lebbe, Celeste
    Sandhu, Shahneen Kaur
    Grignani, Giovanni
    Hennessy, Meliessa G.
    Hildemann, Steven
    Reed, Josh
    Hariharan, Subramanian
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database
    Mortier, Laurent
    Blom, Astrid
    van Hille, Benoit
    Samimi, Mahtab
    Luciani, Laura
    Cahuzac, Capucine
    Robert, Caroline
    Quereux, Gaelle
    Maubec, Eve
    Miotti, Hakima
    Maillard, Cathy
    Aubin, Francois
    Lenormand, Cedric
    Solbes, Marie-Noelle
    Joly, Pascal
    Kachaner, Isabelle
    Lebbe, Celeste
    Dutriaux, Caroline
    Saiag, Philippe
    EUROPEAN JOURNAL OF CANCER, 2024, 209
  • [4] Second-line (2L) real-world treatment (tx) patterns and outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) treated with first-line (1L) immuno-oncology (IO) monotherapy (mono tx)
    Talbot, D.
    Fish, S. M.
    Ong, T. Jin
    Flick, E. D.
    Waterhouse, D. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe
    Becker, Juergen C.
    Lorenz, Eva
    Ugurel, Selma
    Eigentler, Thomas K.
    Kiecker, Felix
    Pfoehler, Claudia
    Kellner, Ivonne
    Meier, Friedegund
    Kaehler, Katharina
    Mohr, Peter
    Berking, Carola
    Haas, Gabriele
    Helwig, Christoph
    Oksen, Dina
    Schadendorf, Dirk
    Mahnkel, Lisa
    Bharmal, Murtuza
    ONCOTARGET, 2017, 8 (45) : 79731 - 79741
  • [6] REAL-WORLD OUTCOMES OF PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA TREATED WITH SECOND-LINE OR LATER CHEMOTHERAPY IN A COMMUNITY ONCOLOGY SETTING IN THE UNITED STATES
    Cowey, C. L.
    Mahnke, L.
    Espirito, J.
    Fox, P.
    Helwig, C.
    Oksen, D.
    Bharmal, M.
    VALUE IN HEALTH, 2016, 19 (07) : A717 - A717
  • [7] Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) Tx: Results from IMPACT UC
    Bilen, M. A.
    Xi, A. D.
    Wong, A.
    Schroeder, A.
    Kim, R.
    Liu, F. X.
    Peng, J.
    Robinson, S.
    Bhanegaonkar, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S713 - S713
  • [8] COST-EFFECTIVENES ANALYSIS OF AVELUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN RUSSIA
    Avxentyev, N. A.
    Frolov, M.
    Makarov, A.
    Palencia, R.
    Kudelya, O., V
    Kovaleva, E. R.
    VALUE IN HEALTH, 2019, 22 : S511 - S511
  • [9] First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study.
    D'Angelo, Sandra P.
    Russell, Jeffrey
    Hassel, Jessica Cecile
    Lebbe, Celeste
    Chmielowski, Bartosz
    Rabinowits, Guilherme
    Terheyden, Patrick
    Brownell, Isaac
    Zwiener, Isabella
    Bajars, Marcis
    Hennessy, Meliessa
    Kaufman, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Real-world (RW) treatment (tx) patterns and clinical outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) in the US community setting.
    Brown-Bickerstaff, Cherrishe
    Conkling, Paul R.
    Banuelos, Rosa
    Perez-Torrealba, Jose Ricardo
    Hall, Tasha D.
    Samant, Navendu
    Zhang, Yue
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
12345